Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-25T11:03:05.220Z Has data issue: false hasContentIssue false

Chapter 2 - Prescribing Practice

Published online by Cambridge University Press:  07 November 2024

By
Gyles Glover ,
David Gerrard  and
David M. L. Branford
Edited by
David M. L. Branford ,
Satheesh K. Gangadharan ,
Mary Barrett  and
Regi T. Alexander
David M. L. Branford
Affiliation:
Independent Pharmacy Consultant
Satheesh K. Gangadharan
Affiliation:
Leicestershire Partnership NHS Trust
Mary Barrett
Affiliation:
Leicestershire Partnership NHS Trust
Regi T. Alexander
Affiliation:
Hertfordshire Partnership University NHS Foundation Trust
Get access

Summary

There are many studies of the prescribing of psychotropic medications for people with intellectual disability. This chapter provides data about that prescribing, the issues associated with the data and the trends in usage. Excessive or unnecessary prescribing of psychotropic medication that exposes individuals to unwanted side-effects and imposes unwarranted costs on services has been the focus of many medications review programmes. This section will review outcomes data from medication reduction programmes for individuals with intellectual disability and present practitioner guidelines. The NHS England programme STOMP (Stopping The Over-Medication of People with a learning disability and autistic people) and STAMP (Supporting Treatment and Appropriate Medication use in Paediatrics) has been the focus for many initiatives in England, resulting in the generation of many resources to assist both professions and non-professionals involved with intellectual disability.

Keywords

psychotropic medicationprescribingmedication review programmesSTOMPSTAMPmedication withdrawal
Type
Chapter
Information
The Frith Prescribing Guidelines for People with Intellectual Disability , pp. 13 - 30
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Accreditation Council for Services for Mentally Retarded and Other Developmental Persons (1977). Standards for Services for Developmentally Disabled Individuals. Chicago: Joint Commission on Accreditation of Hospitals.Google Scholar
Ahmed, Z., Fraser, W., Kerr, M. P., et al. (2000). Reducing antipsychotic medication in people with a learning disability. British Journal of Psychiatry, 178, 42–6.Google Scholar
Ashton Manual (n.d.). Benzodiazepines: How They Work and How to Withdraw. www.benzo.org.uk/manual/bzsched.htm.Google Scholar
Branford, D. (1996a). A review of antipsychotic drugs prescribed for people with learning disability who live in Leicestershire. Journal of Intellectual Disability Research, 40, 4 358–68.Google ScholarPubMed
Branford, D. (1996b). Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. Journal of Intellectual Disability Research; 40, 322–9.Google ScholarPubMed
Branford, D., Gerrard, D., Saleem, N., Shaw, C., & Webster, A. (2019a). Stopping over-medication of people with intellectual disability, Autism or both (STOMP) in England part 1 – history and background of STOMP. Advances in Mental Health and Intellectual Disabilities, 13(1), pp. 31–40. https://doi.org/10.1108/AMHID-02-2018-0004.CrossRefGoogle Scholar
Branford, D., Gerrard, D., Saleem, N., Shaw, C., & Webster, A. (2019b). Stopping over-medication of people with an intellectual disability, autism or both (STOMP) in England part 2 – the story so far. Advances in Mental Health and Intellectual Disabilities, 13(1), 41–51. https://doi.org/10.1108/AMHID-02-2018-0005.CrossRefGoogle Scholar
Cooper, S. A., Smiley, E., Morrison, J., Williamson, A. & Allan, L. (2007). Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. British Journal of Psychiatry, 190, 27–35.CrossRefGoogle ScholarPubMed
de Kuijper, G. M., Evenhuis, H., Minderaa, R., & Hoekstra, P. J. (2014). Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. Journal of Intellectual Disability Research, 58, 71–83.CrossRefGoogle ScholarPubMed
Department of Health (2012), Transforming care: A national response to Winterbourne View Hospital. Department of Health Review: Final report, Department of Health, London. www.gov.uk/government/publications/winterbourne-view-hospital-department-of-health-review-and-response.Google Scholar
Findholt, N. E., & Emmett, C. G. (1990). Impact of interdisciplinary team review on psychotropic drug use with persons who have mental retardation. Mental Retardation, 28(1), 41–6.Google ScholarPubMed
Gerrard, D., Rhodes, J., Lee, R., & Ling, J. (2019), Using positive behavioural support for STOMP challenge. Advances in Mental Health and Intellectual Disabilities, 13(¾), 102–12.CrossRefGoogle Scholar
Glover, G., Williams, R., Branford, D., Holland, A., & Strydom, A. (2014). Use of medication for challenging behaviour in people with intellectual disability. British Journal of Psychiatry, 2054(1), 6–7. https://doi.org/10.1192/bjp.bp.113.141267.CrossRefGoogle Scholar
Jauernig, R., & Hudson, A. (1995) Evaluation of an Interdisciplinary Review Committee managing the use of psychotropic medication with people with intellectual disabilities. Australia and New Zealand Journal of Developmental Disabilities, 20, 51–61.CrossRefGoogle Scholar
Lee, R. M, Rhodes, J. A., & Gerrard, D. (2018). Positive Behavioural Support as an alternative to medication. Tizard Learning Disability Review, 24(1), 1–8. https://doi.org/10.1108/TLDR-06-2018-0018.CrossRefGoogle Scholar
Lepler, S., Hodas, A., & Cotter-Mack, A. (1993). Implementation of an interdisciplinary psychotropic drug review process for community based facilities. Mental Retardation, 31(5), 307–15.Google ScholarPubMed
McNamara, R., Randell, E., Gillespie, D., et al. (2017). A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for adults with learning disabilities. Health Technology Assessment, 21(47), 1–92. https://doi.org/10.3310/hta21470.CrossRefGoogle ScholarPubMed
Mehta, H., & Glover, G. (2019) Psychotropic drugs and people with learning disabilities or autism, 2019. Public Health England. www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-executive-summary.Google Scholar
Nabhanizadeh, A., Oppewal, A., Boot, F. H., & Maes‐Festen, D. (2019). Effectiveness of medication reviews in identifying and reducing medication‐related problems among people with intellectual disabilities: A systematic review. Journal of Applied Research in Intellectual Disabilities, 32, 750–761. https://doi.org/10.1111/jar.12580.CrossRefGoogle ScholarPubMed
NHS Digital (2022) Health and Care of People with Learning Disabilities. Data series/Collection. https://digital.nhs.uk/data-and-information/publications/statistical/health-and-care-of-people-with-learning-disabilities.Google Scholar
National Institute for Health and Care Excellence (NICE) (2015). Challenging behaviour and learning disabilities: Prevention and interventions for people with learning disabilities whose behaviour challenges. National Institute for Health and Care Excellence. www.nice.org.uk/guidance/ng11.Google Scholar
National Institute for Health and Care Excellence (NICE) (2016). Mental health problems in people with learning disabilities: prevention, assessment and management NG54. www.nice.org.uk/guidance/ng54.Google Scholar
NHS (2019). Long term plan. www.longtermplan.nhs.uk/.Google Scholar
NHS England (2016). Doctors urged to help stop ‘chemical restraint’ as leading health professionals sign joint pledge. www.england.nhs.uk/2016/06/over-medication-pledge/.Google Scholar
NHS England (2019). Stopping the overmedication of children and young people with a learning disability, autism or both (STOMP) and supporting treatment and appropriate medication in paediatrics (STAMP). www.england.nhs.uk/learning-disabilities/improving-health/stamp/.Google Scholar
NHS England (2016a). Stopping Over-Medication of People with a Learning Disability (STOMPLD) Pledge. www.england.nhs.uk/2016/06/over-medication-pledge/.Google Scholar
NHS England (2016b). Stopping Over-Medication of People with a Learning Disability (STOMPLD). www.england.nhs.uk/learning-disabilities/improving-health/stomp/?UID=4643034442024219163158.Google Scholar
Public Health England (2019). Psychotropic drugs and people with learning disabilities or autism. www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism.Google Scholar
Royal College of Psychiatrists: Faculty of Psychiatry of Intellectual Disability Report (2016). Psychotropic drug prescribing for people with intellectual disabilities, mental health problems and/or behaviours that challenge: practice guidelines. FR/ID/09 http://www.rcpsych.ac.uk/pdf/FR_ID_09_for_website.pdf.Google Scholar
Royal College of Psychiatry Position Statement PS05/21 (2021). Stopping the overmedication of people with intellectual disability, autism or both (STOMP) and supporting treatment and appropriate medication in paediatrics (STAMP). www.rcpsych.ac.uk/docs/default-source/improving-care/better-mh-policy/position-statements/position-statement-ps0521-stomp-stamp.pdf?sfvrsn=684d09b3_6.Google Scholar
Sheehan, R., & Hassiotis, A. (2017). Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: A systematic review. The Lancet Psychiatry, 4(3), 238–56.CrossRefGoogle ScholarPubMed
Smith, C., Felce, D., Ahmed, Z., et al. (2002). Sedative effects on responsiveness: Evaluating the reduction of antipsychotic medication in people with intellectual disabilities using a conditional probability approach. Journal of Intellectual Disability Research, 46, 464–71.CrossRefGoogle Scholar
Zaal, R. J., Ebbers, S., Borms, M., et al. (2016). Medication review using a Systematic Tool to Reduce Inappropriate Prescribing (STRIP) in adults with an intellectual disability: A pilot study. Research in Developmental Disabilities, 55, 132–42. https://doi.org/10.1016/j.ridd.2016.03.014.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×